{"id":112852,"date":"2009-12-08T15:51:00","date_gmt":"2009-12-08T20:51:00","guid":{"rendered":"tag:typepad.com,2003:post-6a00d8341c89dd53ef0128758d9eda970c"},"modified":"2009-12-08T15:50:08","modified_gmt":"2009-12-08T20:50:08","slug":"medical-journal-report-adverse-drug-reactions-and-pulmonary-embolism-are-often-difficult-for-doctors-to-diagnose","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/112852","title":{"rendered":"Medical Journal Report: Adverse Drug Reactions And Pulmonary Embolism Are Often Difficult For Doctors To Diagnose"},"content":{"rendered":"<div xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<p><strong><span style=\"FONT-SIZE: 14px; FONT-FAMILY: \"><span style=\"FONT-SIZE: 15px; FONT-FAMILY: \"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: \">These Commonly Missed Diagnoses Are Particularly Relevant To Women Using YAZ, Yasmin, And Ocella, As Well As NuvaRing And Ortho Evra<\/span><\/span><\/span><\/strong><\/p>\n<p><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><span style=\"FONT-SIZE: 16px; FONT-FAMILY: Verdana\"><font size=\"2\"><strong>(Posted by Tom Lamb at <a href=\"http:\/\/www.drug-injury.com\/\" ><span style=\"COLOR: #003366\"><font size=\"2\"><strong>DrugInjuryWatch.com<\/strong><\/font><\/span><\/a><font size=\"2\"><strong>)<\/strong><\/font><\/strong><\/font><\/span><\/span><\/span><\/span><\/p>\n<p>The November 9, 2009 issue of the <em>Archives of Internal Medicine<\/em> included an article, <a href=\"http:\/\/archinte.ama-assn.org\/cgi\/content\/abstract\/169\/20\/1881\" >&#8220;Diagnostic Error in Medicine &#8212; Analysis of 583 Physician-Reported Errors&#8221;<\/a>, which should be of particular interest to women using the following birth control products: YAZ \/ Yasmin \/ Ocella; NuvaRing; and, Ortho Evra.<\/p>\n<p>The reason for their likely interest, or concern, involves the combination of two facts.<\/p>\n<p>First, this survey of doctors found that adverse drug reactions and pulmonary embolism are the two most common diagnostic errors committed or observed by those doctors.<\/p>\n<p>Second, thromboembolic events such as pulmonary embolism (PE) and deep vein thrombosis (DVT) are adverse reactions that have been associated with these several birth control methods.<\/p>\n<p>To learn more about the adverse drug reactions aspect of this matter &#8212; in particular, the increased risk developing of blood clots that can cause a pulmonary embolism &#8212; we offer these resources:<\/p>\n<p><a href=\"http:\/\/www.druginjurylaw.com\/YAZYasminOcella-Side-Effects.htm\" >How And Why YAZ, Yasmin, And Ocella Pills Might Cause A Higher Rate Of Blood Clots In Women<\/a><\/p>\n<p><a href=\"http:\/\/www.druginjurylaw.com\/NuvaRing-Side-Effects.html\" >NuvaRing Birth Control Device Use Can Cause Blood Clots and Related Serious Side Effects<\/a><\/p>\n<p><a href=\"http:\/\/www.druginjurylaw.com\/OrthoEvraLabel.html\" >Ortho Evra Birth Control Patch: September 2006 Warning About Serious Blood Clot Risks<\/a><\/p>\n<p>To learn more about the pulmonary embolism aspect of this matter, we offer this resource:<\/p>\n<p><a href=\"http:\/\/www.druginjurylaw.com\/PE-DVT-Blood-Clots-Symptoms-Treatment-Recovery.htm\" >Pulmonary Embolism And Deep Vein Thrombosis: Symptoms, Treatment, and Recovery<\/a><\/p>\n<p>For a complete collection of our articles about these birth control methods as well as selected news reports, see the following:<\/p>\n<p><a href=\"http:\/\/www.drug-injury.com\/druginjurycom\/focus-on-yaz-yasmin-ocella-drug-injury-watch-blog.html\" >Focus On Yaz, Yasmin, And Ocella<br \/><\/a><\/p>\n<p><a href=\"http:\/\/www.drug-injury.com\/druginjurycom\/focus-on-nuvaring-drug-injury-watch-blog.html\" >Focus On NuvaRing<\/a><\/p>\n<p>Our law firm is currently handling\u00a0personal injury\u00a0claims for women who have suffered a serious side effect while using YAZ, Yasmin, and Ocella, as well as NuvaRing and Ortho Evra.\u00a0 We also represent the families of women who have died while using one of these birth control methods in wrongful death lawsuits.<\/p>\n<p>______________________________________________________________________________<\/p>\n<p><a href=\"http:\/\/www.druginjurylaw.com\/\" ><strong><span style=\"FONT-SIZE: 14px; FONT-FAMILY: \"><font color=\"#810081\">DrugInjuryLaw.com<\/font><\/span><\/strong><\/a>: <span style=\"COLOR: #ff0000; FONT-FAMILY: \"><span style=\"COLOR: #80c0ff; FONT-FAMILY: \"><span style=\"COLOR: #800000; FONT-FAMILY: \"><span style=\"COLOR: #302449; FONT-FAMILY: \"><strong>Legal Information And News About Prescription Drug Side Effects<\/strong><\/span><\/span><\/span><\/span><\/p>\n<p><script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F10%2Fdrug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A\/\/www.drug-injury.com\/druginjurycom\/2009\/10\/drug-safety-experts-urge-fda-to-make-drug-safety-info-more-accessible-to-patients--matthew-perrone--ap-business-writer--419.html&amp;showad=true\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fbyetta-exenatide-kidney-function-renal-failure-fda-dear-doctor-label-change-october-2009.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Faranesp-darbepoetin-alfa-associated-with-heightened-stroke-risk-amgen-treat-study-nejm-october.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fanemia-drugs-aranesp-procrit-blood-clots-study-esas-thromboembolism-dvt-pe-stroke.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fconsumers-unions-safe-patient-project-forum-webcast-to-err-is-human-to-delay-is-deadly.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fdrug-industry-document-archive-dida-ucsf-november-2009-additions.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fyaz-drsp-safety-inas-oc-study-venous-thrombosis-pulmonary-embolism-myocardial-infarction-cerebrovascular-accidents.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F11%2Fmeridia-stroke-heart-attack-cardiac-death-fda-sibutramine-early-communication.html\" type=\"text\/javascript\"><\/script><br \/>\n<script src=\"http:\/\/feeds.feedburner.com\/~s\/drug-injury-watch?i=http%3A%2F%2Fwww.drug-injury.com%2Fdruginjurycom%2F2009%2F12%2Ffosamax-onj-side-effect-osteonecrosis-jaw-bisphosphonates-medical-journal-articles-november-2009.html\" type=\"text\/javascript\"><\/script><\/div>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=MjVKOO6LdTg:b1K0lt9kvtc:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=MjVKOO6LdTg:b1K0lt9kvtc:F7zBnMyn0Lo\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=MjVKOO6LdTg:b1K0lt9kvtc:F7zBnMyn0Lo\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=MjVKOO6LdTg:b1K0lt9kvtc:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=MjVKOO6LdTg:b1K0lt9kvtc:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=MjVKOO6LdTg:b1K0lt9kvtc:l6gmwiTKsz0\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?d=l6gmwiTKsz0\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?a=MjVKOO6LdTg:b1K0lt9kvtc:gIN9vFwOqvQ\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/drug-injury-watch?i=MjVKOO6LdTg:b1K0lt9kvtc:gIN9vFwOqvQ\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/drug-injury-watch\/~4\/MjVKOO6LdTg\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>These Commonly Missed Diagnoses Are Particularly Relevant To Women Using YAZ, Yasmin, And Ocella, As Well As NuvaRing And Ortho Evra (Posted by Tom Lamb at DrugInjuryWatch.com) The November 9, 2009 issue of the Archives of Internal Medicine included an article, &#8220;Diagnostic Error in Medicine &#8212; Analysis of 583 Physician-Reported Errors&#8221;, which should be of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-112852","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/112852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=112852"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/112852\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=112852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=112852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=112852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}